SWOG CANCER RESEARCH NETWORK

Broadcast Date: October 01, 2026

TO: ALL NATIONAL CLINICAL TRIALS NETWORK (NCTN) MEMBERS; CTSU

FROM: SWOG Network Operations Center (protocols@swog.org)

RE: IND Approval Letter Request Procedures

MEMORANDUM – IND APPROVAL LETTER REQUEST

The purpose of this memorandum is to provide instructions for obtaining documentation of FDA IND approval/study-may-proceed letters for SWOG trials. Sites may use this documentation described below when providing IND information to their institutional IRB.

For SWOG-held INDs:

For trials conducted under a SWOG-held IND, please contact protocols@swog.org for identification of the applicable IND(s). The Study May Proceed letter identifies the applicable "Southwest Oncology Group" IND(s) and confirms that the protocol was submitted to the U.S. Food and Drug Administration (FDA) as an initial or as an amendment to the SWOG-sponsored IND(s) for the investigational agent(s).

Please refer to the protocol title page to identify the IND holder.

For CTEP-held INDs:

For trials conducted under a CTEP-held IND, contact protocols@swog.org to request a copy of the **NCI Notice of Protocol Approval.**

The letter identifies the DCTD/NCI IND(s) and confirms that the protocol has been submitted to the U.S. Food and Drug Administration (FDA) as an amendment to the NCI-sponsored IND(s) for the investigational agent(s).

Please refer to the protocol title page to identify the IND holder.

Please contact protocols@swog.org with any questions.

This memorandum serves to notify the NCI and SWOG Statistics and Data Management Center.

cc: PROTOCOL & INFORMATION OFFICE